Antibody–drug conjugate targeting CD30; the anti-CD30 monoclonal antibody is internalized and releases MMAE, a microtubule-disrupting agent, leading to mitotic arrest and apoptosis (may also mediate ADCC).
Anti-CD30 antibody-drug conjugate that binds CD30 on tumor cells, is internalized, and undergoes linker cleavage to release monomethyl auristatin E (MMAE). MMAE inhibits tubulin polymerization, leading to G2/M mitotic arrest and apoptosis; the antibody may also mediate ADCC.
YES
DIRECT
The anti-CD30 ADC binds CD30, is internalized, and releases MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptosis; the Fc can also mediate ADCC.
Antibody–drug conjugate targeting CD30; the anti-CD30 monoclonal antibody is internalized and releases MMAE, a microtubule-disrupting agent, leading to mitotic arrest and apoptosis (may also mediate ADCC).
Anti-CD30 antibody-drug conjugate that binds CD30 on tumor cells, is internalized, and undergoes linker cleavage to release monomethyl auristatin E (MMAE). MMAE inhibits tubulin polymerization, leading to G2/M mitotic arrest and apoptosis; the antibody may also mediate ADCC.
NO
INDIRECT
Brentuximab vedotin targets CD30, is internalized, and releases MMAE that binds the beta-tubulin (vinca) site to block microtubule polymerization, causing G2/M arrest and apoptosis. Killing is determined by CD30 targeting, not by beta-tubulin expression itself.
A plasmid DNA therapeutic vaccine encoding a secreted, detoxified HPV16 E7 antigen fused to HSP70 to enhance dendritic-cell uptake and cross-presentation, priming HPV16-specific T-cell responses.
Plasmid DNA vaccine encoding a secreted, detoxified HPV16 E7 antigen fused to HSP70. After delivery, host cells express and secrete E7-HSP70, which enhances dendritic-cell uptake and cross-presentation, leading to MHC I/II presentation and priming of HPV16-specific CD8+ and CD4+ T-cell responses.
NO
INDIRECT
The DNA vaccine expresses and secretes detoxified E7 fused to HSP70 to enhance dendritic-cell uptake and cross-presentation, priming HPV16 E7–specific CD8+ T cells. These CTLs then kill HPV16 E7–expressing tumor/infected cells via MHC I recognition and perforin/granzyme; the detoxified E7 itself is an immunogen, not a direct cytotoxic target.
A plasmid DNA therapeutic vaccine encoding a secreted, detoxified HPV16 E7 antigen fused to HSP70 to enhance dendritic-cell uptake and cross-presentation, priming HPV16-specific T-cell responses.
Plasmid DNA vaccine encoding a secreted, detoxified HPV16 E7 antigen fused to HSP70. After delivery, host cells express and secrete E7-HSP70, which enhances dendritic-cell uptake and cross-presentation, leading to MHC I/II presentation and priming of HPV16-specific CD8+ and CD4+ T-cell responses.
NO
INDIRECT
HSP70–E7 uses CD91/LRP1 on dendritic cells for uptake and cross-presentation, priming HPV16 E7–specific CTLs. The CTLs kill HPV16 E7–expressing tumor cells via perforin/granzyme; CD91+ dendritic cells are not killed.
A plasmid DNA therapeutic vaccine encoding a secreted, detoxified HPV16 E7 antigen fused to HSP70 to enhance dendritic-cell uptake and cross-presentation, priming HPV16-specific T-cell responses.
Plasmid DNA vaccine encoding a secreted, detoxified HPV16 E7 antigen fused to HSP70. After delivery, host cells express and secrete E7-HSP70, which enhances dendritic-cell uptake and cross-presentation, leading to MHC I/II presentation and priming of HPV16-specific CD8+ and CD4+ T-cell responses.
NO
INDIRECT
HSP70 in the vaccine activates TLR4 on antigen‑presenting cells to enhance cross‑presentation, generating HPV16 E7‑specific CTLs that kill E7+ tumor cells; TLR4-expressing cells are not targeted or killed.